Fresenius Kabi Gets FDA Approval for Biosimilar Stimufend

Fresenius Kabi said it received FDA approval for Stimufend, making it the company’s first approved US biosimilar.

• For use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
• Expects to launch the product in a prefilled syringe early next year and in an on-body injector following FDA approval

NOTE

• Fresenius SE & Co. rose 1.2% to EU25.11 as of last close
  • The average 12-month price target of EU36.46 is 45.2% above the current price
  • 14 buys, 8 holds, 0 sells

To view the source of this information, click here

To contact ...